Clinical Trial: NCT06793553
Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC
Status:
RECRUITINGPhase:
Phase 2| Lead Sponsor: | Japan Breast Cancer Research Group |
| Information Provided By: | Japan Breast Cancer Research Group |
| Last Update Posted: | 2025-01-30 |
Study Overview
Brief Summary
The objective of this research is to evaluate the efficacy of the treatment strategy to administer atezolizumab + nab-paclitaxel (PTX) following 2 cycles of induction therapy with PTX + bevacizumab (induction treatment strategy) in programmed cell death ligand-1 (PD-L1)-positive metastatic triple-negative breast cancer (mTNBC) in comparison with the standard atezolizumab + nab-PTX therapy.
Official Title
Conditions
Intervention / Treatment
- Drug: Induction therapy
Other Study ID Numbers
- JBCRG-M10
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | Japan Breast Cancer Research Group |
| Information Provided By: | Japan Breast Cancer Research Group |
| Last Update Posted: | 2025-01-30 |
Study Overview
Brief Summary
The objective of this research is to evaluate the efficacy of the treatment strategy to administer atezolizumab + nab-paclitaxel (PTX) following 2 cycles of induction therapy with PTX + bevacizumab (induction treatment strategy) in programmed cell death ligand-1 (PD-L1)-positive metastatic triple-negative breast cancer (mTNBC) in comparison with the standard atezolizumab + nab-PTX therapy.
Official Title
Conditions
Intervention / Treatment
- Drug: Induction therapy
Other Study ID Numbers
- JBCRG-M10